Alopecia-intellectual disability syndrome 4 (APMR4; OMIM #618840) is a very rare autosomal recessive neuroectodermal syndrome caused by biallelic pathogenic variants in LSS (lanosterol synthase), which maps to chromosome 21q22.3. It is characterized by congenital alopecia/atrichia (absent scalp hair with sparse eyebrows and eyelashes) combined with variable-degree intellectual disability, frequently with developmental delay and early-onset epilepsy, and variable additional features (scaly skin/ichthyosis, microcephaly, thin corpus callosum, hypotonia, and genital abnormalities in males). LSS catalyzes the rate-limiting cyclization of (S)-2,3-oxidosqualene to lanosterol, the first sterol of the cholesterol biosynthesis pathway; how partial loss of this enzyme produces alopecia and neurodevelopmental impairment, while circulating cholesterol stays normal, is not fully established. This entry is one molecularly characterized member of the broader alopecia-intellectual disability syndrome (APMR) group (MONDO:0008756), a multi-gene family whose four types are genetically distinct: APMR1 is caused by AHSG, APMR4 (this entry) by LSS, and the APMR2 and APMR3 loci remain uncharacterized. Because these are separate diseases with different genes rather than a single-gene severity spectrum, the APMR group is best modeled as a kb/groupings/ Grouping over the individual member Disease entries once at least two members are curated, NOT as one umbrella Disease with has_subtypes. APMR4 is curated here as the flagship member (strongest, most recent gene-disease evidence); a grouping is deferred until a second member (e.g. AHSG/APMR1) exists.
Ask a research question about Alopecia-Intellectual Disability Syndrome 4. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Alopecia-Intellectual Disability Syndrome 4
synonyms:
- APMR4
- Alopecia with mental retardation syndrome 4
- LSS-related alopecia-intellectual disability syndrome
- Alopecia-intellectual disability syndrome type 4
creation_date: '2026-08-17T12:00:00Z'
category: Mendelian
description: >
Alopecia-intellectual disability syndrome 4 (APMR4; OMIM #618840) is a very rare
autosomal recessive neuroectodermal syndrome caused by biallelic pathogenic
variants in LSS (lanosterol synthase), which maps to chromosome 21q22.3. It is
characterized by congenital alopecia/atrichia (absent scalp hair with sparse
eyebrows and eyelashes) combined with variable-degree intellectual disability, frequently
with developmental delay and early-onset epilepsy, and variable additional
features (scaly skin/ichthyosis, microcephaly, thin corpus callosum, hypotonia,
and genital abnormalities in males). LSS catalyzes the rate-limiting cyclization
of (S)-2,3-oxidosqualene to lanosterol, the first sterol of the cholesterol
biosynthesis pathway; how partial loss of this enzyme produces alopecia and
neurodevelopmental impairment, while circulating cholesterol stays normal, is
not fully established.
This entry is one molecularly characterized member of the broader
alopecia-intellectual disability syndrome (APMR) group (MONDO:0008756), a
multi-gene family whose four types are genetically distinct: APMR1 is caused by
AHSG, APMR4 (this entry) by LSS, and the APMR2 and APMR3 loci remain
uncharacterized. Because these are separate diseases with different genes rather
than a single-gene severity spectrum, the APMR group is best modeled as a
kb/groupings/ Grouping over the individual member Disease entries once at least
two members are curated, NOT as one umbrella Disease with has_subtypes. APMR4 is
curated here as the flagship member (strongest, most recent gene-disease
evidence); a grouping is deferred until a second member (e.g. AHSG/APMR1) exists.
disease_term:
preferred_term: alopecia-intellectual disability syndrome 4
term:
id: MONDO:0030009
label: alopecia-intellectual disability syndrome 4
inheritance:
- name: Autosomal Recessive
inheritance_term:
preferred_term: Autosomal recessive inheritance
term:
id: HP:0000007
label: Autosomal recessive inheritance
description: >
APMR4 is inherited in an autosomal recessive manner; affected individuals
carry biallelic (homozygous or compound heterozygous) LSS variants, and
heterozygous carriers are asymptomatic. Consanguinity is frequent in reported
families.
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "It is a rare autosomal recessive condition characterized by hypotrichosis and intellectual disability (ID) or developmental delay (DD), frequently associated with early-onset epilepsy and other dermatological features."
explanation: Establishes autosomal recessive inheritance and the cardinal phenotype.
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We reported ten APMR individuals from six unrelated families with biallelic variants in LSS."
explanation: Biallelic variants across six families support recessive inheritance.
prevalence:
- population: Worldwide
measure_type: POINT_PREVALENCE
prevalence_class: BELOW_1_IN_1000000
rate_per_100000: 0.1
notes: >-
APMR (all types) carries a predicted estimated prevalence of less than
1:1,000,000 worldwide; APMR4 specifically is documented only in a small
number of molecularly proven families rather than by formal epidemiology.
evidence:
- reference: PMID:38800572
reference_title: "Clinical and genetic analyses of APMR4 syndrome caused by novel biallelic LSS variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "with a predicted estimated prevalence of less than 1:1,000,000 globally"
explanation: >-
"Less than 1:1,000,000" supports the BELOW_1_IN_1000000 class (the estimate
is for APMR overall, not APMR4 specifically).
- reference: PMID:33881165
reference_title: "Alopecia-mental retardation syndrome: Molecular genetics of a rare neuro-dermal disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "according to a predictive estimate, it prevails with the ratio of 1 in 1,000,000 persons worldwide"
explanation: Predictive prevalence estimate for the APMR group.
pathophysiology:
- name: Biallelic LSS Loss-of-Function
role: trigger
biological_scale: MOLECULAR
description: >
Biallelic pathogenic LSS variants (missense, splicing, nonsense, and
frameshift alleles) reduce lanosterol synthase activity. Most affected
individuals carry at least one hypomorphic missense allele; complete loss of
enzyme activity is presumed incompatible with life, consistent with the
variable (embryonic-to-perinatal) lethality of homozygous Lss-null mice
(see animal_models). A truncating LSS allele was shown to reduce LSS protein
expression in patient cells.
gene:
preferred_term: LSS
term:
id: hgnc:6708
label: LSS
molecular_functions:
- preferred_term: lanosterol synthase activity
term:
id: GO:0000250
label: lanosterol synthase activity
modifier: DECREASED
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Our data suggest LSS as a major gene causing a rare recessive neuroectodermal syndrome."
explanation: Establishes LSS as the causal gene for APMR4.
- reference: PMID:38800572
reference_title: "Clinical and genetic analyses of APMR4 syndrome caused by novel biallelic LSS variants."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Analysis via WB experiment indicated that c.369 > G reduced the protein expression level of LSS."
explanation: A truncating LSS allele reduces LSS protein, supporting loss-of-function.
downstream:
- target: Impaired Cholesterol Biosynthesis
description: >-
Reduced lanosterol synthase activity impairs the cyclization step that
commits the sterol pathway to cholesterol.
causal_link_type: DIRECT
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In the cholesterol biosynthesis pathway, lanosterol synthase leads to the cyclization of (S)-2,3-oxidosqualene into lanosterol."
explanation: Places LSS at the committed cyclization step of cholesterol biosynthesis.
- name: Impaired Cholesterol Biosynthesis
biological_scale: MOLECULAR
description: >
Lanosterol synthase catalyzes the rate-limiting conversion of
(S)-2,3-oxidosqualene to lanosterol, the first sterol of the pathway. Reduced
activity is expected to lower local cholesterol synthesis, particularly in
tissues with high demand such as brain and skin. Circulating cholesterol and
its precursors are typically normal in APMR4, indicating that the defect is
tissue-local rather than a systemic hypocholesterolemia.
biological_processes:
- preferred_term: cholesterol biosynthetic process
term:
id: GO:0006695
label: cholesterol biosynthetic process
modifier: DECREASED
evidence:
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "It catalyzes the rate-limiting step in the conversion of (S)-2,3-oxidosqualene into lanosterol."
explanation: Establishes LSS as the rate-limiting enzyme of the affected step.
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "LSS is expressed in many tissues, including the brain, glomerular podocytes, and skin, potentially explaining multi-system involvement and pleiotropic phenotypic manifestations."
explanation: Tissue expression rationalizes the skin and CNS involvement.
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Quantification of cholesterol and its precursors did not reveal noticeable imbalance."
explanation: Systemic sterols are normal, supporting a tissue-local rather than systemic defect.
downstream:
- target: Impaired Hair Follicle Development
description: >-
Cholesterol homeostasis is important for the hair-growth program; its local
disruption impairs hair follicle development.
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
evidence:
- reference: PMID:36251212
reference_title: "Expanding the Phenotypic Spectrum of APMR4 Syndrome Caused by a Novel Variant in LSS Gene and Review of Literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "It encodes lanosterol synthase enzyme which converts (S)-2,3-oxidosqualene to lanosterol in the cholesterol biosynthesis pathway which has the key role of the metabolic pathway in the homeostasis of hair growth."
explanation: Links the cholesterol pathway to hair-growth homeostasis.
- target: Impaired Neurodevelopment
description: >-
The developing brain has a high cholesterol requirement; reduced local
synthesis is proposed to impair neurodevelopment.
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
evidence:
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "LSS is expressed in many tissues, including the brain, glomerular podocytes, and skin, potentially explaining multi-system involvement and pleiotropic phenotypic manifestations."
explanation: Brain expression of LSS underlies the neurodevelopmental arm.
- target: Micropenis
description: >-
Cholesterol biosynthesis is required for normal male genital development
in early fetal life; the LSS defect is proposed to underlie the genital
anomalies seen in affected males.
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
evidence:
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "It is proposed to result from the impairment in the cholesterol biosynthesis pathway due to defective LSS which is essential for the development of normal genitalia in early fetal life."
explanation: Links the cholesterol-biosynthesis defect to the male genital phenotype.
- target: Cryptorchidism
description: >-
The same fetal cholesterol-biosynthesis requirement for normal genital
development is proposed to underlie cryptorchidism in affected males.
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
evidence:
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "It is proposed to result from the impairment in the cholesterol biosynthesis pathway due to defective LSS which is essential for the development of normal genitalia in early fetal life."
explanation: Links the cholesterol-biosynthesis defect to the male genital phenotype.
- target: Ichthyosis
description: >-
LSS is expressed in skin; locally reduced cholesterol biosynthesis is
proposed to underlie the scaly-skin/ichthyosis dermatological phenotype.
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
evidence:
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "LSS is expressed in many tissues, including the brain, glomerular podocytes, and skin, potentially explaining multi-system involvement and pleiotropic phenotypic manifestations."
explanation: Skin expression of LSS underlies the cutaneous (ichthyosis) arm.
- name: Impaired Hair Follicle Development
biological_scale: TISSUE
description: >
Disrupted local cholesterol supply impairs hair follicle development,
producing the congenital alopecia/atrichia (absent scalp hair, eyebrows, and
eyelashes) that is the cardinal cutaneous feature. LSS-related conditions
also span an isolated autosomal recessive hypotrichosis, underscoring the
follicle sensitivity to this enzyme.
biological_processes:
- preferred_term: hair follicle development
term:
id: GO:0001942
label: hair follicle development
modifier: DECREASED
cell_types:
- preferred_term: hair follicle cell
term:
id: CL:0002559
label: hair follicle cell
evidence:
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Pathogenic biallelic variants in LSS are associated with three Mendelian rare disease traits including congenital cataract type 44, autosomal recessive hypotrichosis type 14, and alopecia-intellectual disability syndrome type 4 (APMR4)."
explanation: The LSS hair phenotypes (hypotrichosis and APMR4 alopecia) implicate follicle-level disruption.
downstream:
- target: Congenital Alopecia
description: Impaired follicle development manifests as congenital absence of hair.
causal_link_type: DIRECT
evidence:
- reference: PMID:38800572
reference_title: "Clinical and genetic analyses of APMR4 syndrome caused by novel biallelic LSS variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "It is characterized by congenital alopecia and variable degrees of intellectual disability (ID), frequently associated with developmental delay (DD) and epilepsy."
explanation: Congenital alopecia is a defining manifestation.
- name: Impaired Neurodevelopment
biological_scale: TISSUE
description: >
Reduced local cholesterol biosynthesis in the developing central nervous
system is proposed to impair neurodevelopment, giving rise to variable
intellectual disability and developmental delay and, in many patients,
early-onset epilepsy. Brain MRI abnormalities (thin corpus callosum, mild
cortical atrophy) accompany the clinical picture in some individuals. The
precise molecular route from LSS deficiency to the neurological phenotype
remains unresolved.
biological_processes:
- preferred_term: nervous system development
term:
id: GO:0007399
label: nervous system development
modifier: ABNORMAL
evidence:
- reference: PMID:38800572
reference_title: "Clinical and genetic analyses of APMR4 syndrome caused by novel biallelic LSS variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We studied one patient with LSS-related APMR4 who presented with severe intellectual disability, alopecia, early-onset epilepsy and developmental delay."
explanation: Documents the neurodevelopmental features of APMR4.
downstream:
- target: Intellectual Disability
description: Impaired neurodevelopment produces variable-degree intellectual disability.
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
evidence:
- reference: PMID:36251212
reference_title: "Expanding the Phenotypic Spectrum of APMR4 Syndrome Caused by a Novel Variant in LSS Gene and Review of Literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "alopecia intellectual disability syndromes 4 (APMR4) (OMIM# 618,840) has a wider degree of affection when describing ID ranging from mild to severe"
explanation: APMR4 ID severity ranges from mild to severe.
- target: Early-Onset Epilepsy
description: A subset of patients develop early-onset seizures.
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "frequently associated with early-onset epilepsy and other dermatological features"
explanation: Early-onset epilepsy is a frequent associated feature.
phenotypes:
- name: Congenital Alopecia
category: Clinical
description: >
Congenital total (scalp) alopecia with sparse eyebrows and eyelashes
(alopecia/atrichia) is the cardinal cutaneous manifestation, present from
birth in all reported individuals.
phenotype_term:
preferred_term: Alopecia totalis (congenital, with sparse eyebrows and eyelashes)
term:
id: HP:0007418
label: Alopecia totalis
onset:
onset_category: CONGENITAL
frequency: OBLIGATE
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Total alopecia with sparse eyelashes and eyebrows was noted at birth in all affected individuals."
explanation: Congenital total alopecia was present in all 11 individuals of the LSS/APMR4 cohort (obligate).
- reference: PMID:33881165
reference_title: "Alopecia-mental retardation syndrome: Molecular genetics of a rare neuro-dermal disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "It is characterized by heterogeneous phenotypic features, that is, absence of hair on the scalp, eyelashes, and eyebrows and mild to severe intellectual disability."
explanation: Describes the absence of scalp, eyelash, and eyebrow hair.
- reference: PMID:38800572
reference_title: "Clinical and genetic analyses of APMR4 syndrome caused by novel biallelic LSS variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "She is absence of hair on the eyebrows, eyelashes, and scalp."
explanation: A patient with absence of eyebrow, eyelash, and scalp hair.
- name: Sparse Eyebrows
category: Clinical
description: >
Sparse (to absent) eyebrows accompany the scalp alopecia. The APMR4 cohort
is described with sparse eyebrows/eyelashes; individual patients range from
sparse to complete absence.
phenotype_term:
preferred_term: Sparse eyebrow
term:
id: HP:0045075
label: Sparse eyebrow
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Total alopecia with sparse eyelashes and eyebrows was noted at birth in all affected individuals."
explanation: APMR4 cohort had sparse eyebrows at birth.
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "He had alopecia, sparse hair and eyebrows, prominent forehead"
explanation: The APMR4 proband had sparse hair and eyebrows.
- name: Sparse Eyelashes
category: Clinical
description: >
Sparse (to absent) eyelashes accompany the scalp alopecia; the APMR4 cohort
is described with sparse eyelashes/eyebrows.
phenotype_term:
preferred_term: Sparse eyelashes
term:
id: HP:0000653
label: Sparse eyelashes
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Total alopecia with sparse eyelashes and eyebrows was noted at birth in all affected individuals."
explanation: APMR4 cohort had sparse eyelashes at birth.
- name: Intellectual Disability
category: Clinical
description: >
Intellectual disability of variable degree (mild to severe) is a defining
feature; APMR4 shows a wider ID range than the other APMR types.
phenotype_term:
preferred_term: Intellectual disability (mild to severe)
term:
id: HP:0001249
label: Intellectual disability
frequency: OBLIGATE
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "was considered mild (1/11), moderate (3/11), or severe (7/11)"
explanation: All 11 individuals had intellectual disability (1+3+7 = 11/11; obligate), with a mild-to-severe severity distribution.
- reference: PMID:36251212
reference_title: "Expanding the Phenotypic Spectrum of APMR4 Syndrome Caused by a Novel Variant in LSS Gene and Review of Literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "This syndrome has a clinical heterogeneity mainly exhibited with variable degrees of intellectual disability (ID) and congenital alopecia, as well."
explanation: Variable-degree ID is a cardinal feature.
- name: Global Developmental Delay
category: Clinical
description: Global developmental delay is frequently present, often from birth.
phenotype_term:
preferred_term: Global developmental delay
term:
id: HP:0001263
label: Global developmental delay
frequency: OBLIGATE
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "all presented with congenital alopecia and developmental delay"
explanation: All 11 individuals presented with congenital alopecia and developmental delay (obligate).
- reference: PMID:38800572
reference_title: "Clinical and genetic analyses of APMR4 syndrome caused by novel biallelic LSS variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "It is characterized by congenital alopecia and variable degrees of intellectual disability (ID), frequently associated with developmental delay (DD) and epilepsy."
explanation: Developmental delay is a frequently associated feature.
- name: Early-Onset Epilepsy
category: Clinical
description: >
Early-onset seizures occur in a substantial proportion of patients, with age
of onset ranging from birth into infancy.
phenotype_term:
preferred_term: Early-onset seizure
term:
id: HP:0001250
label: Seizure
temporality: RECURRENT
frequency: FREQUENT
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Epilepsy was also frequent (8/11)."
explanation: Epilepsy in 8/11 (73%) of the cohort supports the FREQUENT band.
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "frequently associated with early-onset epilepsy and other dermatological features"
explanation: Early-onset epilepsy is a frequent associated feature.
- name: Ichthyosis
category: Clinical
description: >
Scaly skin/ichthyosis and other dermatological findings occur in a large
proportion of patients.
phenotype_term:
preferred_term: Scaly skin (ichthyosis)
term:
id: HP:0008064
label: Ichthyosis
frequency: VERY_FREQUENT
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "ichthyosis and erythroderma were found in 9/11 individuals"
explanation: Ichthyosis/erythroderma in 9/11 (82%) of the cohort supports the VERY_FREQUENT band.
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "APMR4 is characterized by alopecia universalis, scaly skin, and variable degrees of psychomotor delay."
explanation: Scaly skin is part of the APMR4 phenotype.
- name: Thin Corpus Callosum
category: Clinical
description: >
Thinning of the corpus callosum is among the brain MRI abnormalities reported
in APMR4.
phenotype_term:
preferred_term: Thin corpus callosum
term:
id: HP:0033725
label: Thin corpus callosum
frequency: FREQUENT
evidence:
- reference: PMID:38800572
reference_title: "Clinical and genetic analyses of APMR4 syndrome caused by novel biallelic LSS variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "dysplasia of the corpus callosum is the most common abnormality in head MRI"
explanation: Corpus callosum dysplasia/thinning is the most common head-MRI abnormality across reported APMR4 patients, supporting the FREQUENT band.
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Rare features associated with APMR4 such as cryptorchidism, micropenis, mild cortical brain atrophy and thin corpus callosum were detected."
explanation: Thin corpus callosum reported as an APMR4 brain finding.
- name: Cerebral Cortical Atrophy
category: Clinical
description: Mild cortical brain atrophy has been reported on neuroimaging.
phenotype_term:
preferred_term: Mild cortical brain atrophy
term:
id: HP:0002120
label: Cerebral cortical atrophy
frequency: OCCASIONAL
evidence:
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "mild cortical brain atrophy and thin corpus callosum were detected"
explanation: Mild cortical atrophy reported as an APMR4 brain finding.
- name: Cryptorchidism
category: Clinical
description: Cryptorchidism is among the genital abnormalities reported in affected males.
phenotype_term:
preferred_term: Cryptorchidism
term:
id: HP:0000028
label: Cryptorchidism
frequency: OCCASIONAL
notes: >-
Sex-restricted (male). In the Besnard cohort, genital abnormalities were
reported in four of the six affected males (4/6 males); OCCASIONAL is kept
as the rate over all patients of both sexes.
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "four males presented with genital abnormalities"
explanation: Genital abnormalities occurred in 4 of the 6 affected males (male-restricted).
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Rare features associated with APMR4 such as cryptorchidism, micropenis, mild cortical brain atrophy and thin corpus callosum were detected."
explanation: Cryptorchidism reported as an APMR4 genital finding in males.
- name: Micropenis
category: Clinical
description: Micropenis has been reported among affected males.
phenotype_term:
preferred_term: Micropenis
term:
id: HP:0000054
label: Micropenis
frequency: OCCASIONAL
notes: >-
Sex-restricted (male). Micropenis was reported in four males with APMR4;
OCCASIONAL is kept as the rate over all patients of both sexes.
evidence:
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Our proband had micropenis, reported in four males with APMR4"
explanation: Micropenis reported in four APMR4 males (male-restricted).
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "cryptorchidism, micropenis, mild cortical brain atrophy and thin corpus callosum were detected"
explanation: Micropenis reported among APMR4 male genital findings.
- name: Generalized Hypotonia
category: Clinical
description: Generalized hypotonia is commonly observed on neurological examination.
phenotype_term:
preferred_term: Generalized hypotonia
term:
id: HP:0001290
label: Generalized hypotonia
frequency: FREQUENT
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "absent or very poor speech in 9/10 individuals, hypotonia in 7/11"
explanation: Hypotonia in 7/11 (64%) of the cohort supports the FREQUENT band.
- reference: PMID:38800572
reference_title: "Clinical and genetic analyses of APMR4 syndrome caused by novel biallelic LSS variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "she was insensitive to sound stimulation, had no eye contact, could not focus on or follow objects, and had hypotonia"
explanation: Hypotonia observed on examination.
- name: Microcephaly
category: Clinical
description: >
Microcephaly is a recurrent but non-constant feature; head circumference
was reduced in a subset of the cohort and markedly so in individual reports.
phenotype_term:
preferred_term: Microcephaly
term:
id: HP:0000252
label: Microcephaly
frequency: FREQUENT
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Microcephaly was not constant (3/8)."
explanation: Microcephaly in 3/8 (38%) of assessed individuals supports the FREQUENT band.
- reference: PMID:36251212
reference_title: "Expanding the Phenotypic Spectrum of APMR4 Syndrome Caused by a Novel Variant in LSS Gene and Review of Literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Our patient exhibited congenital alopecia, microcephaly, global developmental delay, and hypotonia with hyporeflexia."
explanation: An APMR4 proband exhibited microcephaly.
- name: Absent or Poor Speech
category: Clinical
description: >
Absent or very poor expressive speech is among the most frequent
neurodevelopmental features of APMR4.
phenotype_term:
preferred_term: Absent or very poor speech
term:
id: HP:0001344
label: Absent speech
frequency: VERY_FREQUENT
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "absent or very poor speech in 9/10 individuals"
explanation: Absent/very poor speech in 9/10 (90%) supports the VERY_FREQUENT band.
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "absent or poor speech (10/13; 77%)"
explanation: Independently, absent/poor speech was reported in 10/13 (77%) of reviewed subjects.
- name: Lateral Ventricle Dilatation
category: Clinical
description: >
Dilatation/enlargement of the lateral ventricles is a recurrent brain-MRI
finding, reported across multiple independent APMR4 case reports.
phenotype_term:
preferred_term: Dilated lateral ventricles
term:
id: HP:0006956
label: Lateral ventricle dilatation
evidence:
- reference: PMID:38800572
reference_title: "Clinical and genetic analyses of APMR4 syndrome caused by novel biallelic LSS variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Cranial magnetic resonance imaging (MRI) showed enlarged bilateral lateral ventricles"
explanation: Enlarged bilateral lateral ventricles on brain MRI.
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Brain MRI identified mildly dilated lateral ventricles, mild cortical volume loss, and cerebellar vermian hypoplasia."
explanation: Mildly dilated lateral ventricles on brain MRI in an APMR4 proband.
- reference: PMID:36251212
reference_title: "Expanding the Phenotypic Spectrum of APMR4 Syndrome Caused by a Novel Variant in LSS Gene and Review of Literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "moderate dilatation of the lateral ventricle"
explanation: Moderate lateral-ventricle dilatation on brain MRI in an APMR4 proband.
genetic:
- name: LSS Pathogenic Variants
gene_term:
preferred_term: LSS
term:
id: hgnc:6708
label: LSS
association: CAUSAL
notes: >
Biallelic pathogenic LSS variants (chromosome 21q22.3) cause APMR4. Reported
alleles span missense, splice-site, nonsense, and frameshift changes
distributed across the gene; most affected individuals carry at least one
hypomorphic missense allele, and no patient has been reported with two alleles
predicting complete loss of protein, consistent with presumed lethality of
total enzyme absence. LSS is also associated with two other autosomal
recessive traits — congenital cataract type 44 and hypotrichosis simplex type
14 — with an emerging genotype-phenotype correlation across LSS-related
disease.
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We reported ten APMR individuals from six unrelated families with biallelic variants in LSS."
explanation: Establishes biallelic LSS variants as causal across multiple families.
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Pathogenic biallelic variants in LSS are associated with three Mendelian rare disease traits including congenital cataract type 44, autosomal recessive hypotrichosis type 14, and alopecia-intellectual disability syndrome type 4 (APMR4)."
explanation: Places APMR4 within the LSS-related allelic disease spectrum.
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "cases with a more severe phenotype were more likely to have a biallelic combination of a LoF allele plus a missense"
explanation: Emerging genotype-phenotype correlation - a loss-of-function allele in trans with a missense allele trends toward a more severe phenotype.
treatments:
- name: Antiseizure Pharmacotherapy
description: >
Management of the early-onset epilepsy is symptomatic, using antiseizure
medications (e.g. valproic acid, topiramate, clonazepam), often in
combination for refractory seizures; there is no disease-modifying therapy.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: anticonvulsant agent
term:
id: NCIT:C264
label: Anticonvulsant Agent
- preferred_term: clonazepam
term:
id: CHEBI:3756
label: clonazepam
therapeutic_modality: SMALL_MOLECULE
evidence:
- reference: PMID:38800572
reference_title: "Clinical and genetic analyses of APMR4 syndrome caused by novel biallelic LSS variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "She was treated with a combination of antiepileptic treatment with valproic acid (VPA) and TPM at her 6 months old."
explanation: Documents combination antiseizure pharmacotherapy in an APMR4 patient.
- reference: PMID:38800572
reference_title: "Clinical and genetic analyses of APMR4 syndrome caused by novel biallelic LSS variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "clonazepam showed a good therapeutic effect"
explanation: Clonazepam controlled the refractory epilepsy in the reported APMR4 patient.
- name: Supportive and Developmental Care
description: >
Multidisciplinary supportive care addresses developmental delay and
intellectual disability, with early intervention and rehabilitation.
treatment_term:
preferred_term: Supportive Care
term:
id: NCIT:C15747
label: Supportive Care
therapeutic_modality: BEHAVIORAL
- name: Genetic Counseling
description: >
Genetic counseling and, where desired, prenatal testing are offered to
families given the autosomal recessive recurrence risk; prenatal molecular
diagnosis has been performed in reported families.
treatment_term:
preferred_term: Genetic Counseling
term:
id: NCIT:C15240
label: Genetic Counseling
evidence:
- reference: PMID:36251212
reference_title: "Expanding the Phenotypic Spectrum of APMR4 Syndrome Caused by a Novel Variant in LSS Gene and Review of Literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the report gives a hint on the importance of prenatal testing and the proper genetic counseling"
explanation: Highlights the role of genetic counseling and prenatal testing.
diagnosis:
- name: Molecular genetic testing
description: >-
APMR4 is confirmed molecularly by identifying biallelic pathogenic LSS
variants, typically by whole-exome/genome sequencing; genetic testing
underpins prenatal diagnosis and genetic counseling for at-risk families.
diagnosis_term:
preferred_term: molecular genetic testing
term:
id: NCIT:C15709
label: Genetic Testing
results: Biallelic pathogenic LSS variants confirming APMR4.
evidence:
- reference: PMID:38800572
reference_title: "Clinical and genetic analyses of APMR4 syndrome caused by novel biallelic LSS variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Our results emphasize the importance of genetic testing of patients with APMR4 syndrome, to provide prenatal diagnosis and proper genetic counseling for families with the syndrome."
explanation: Molecular genetic testing is the diagnostic pathway and enables prenatal diagnosis/counseling.
- name: Brain magnetic resonance imaging
description: >-
Brain MRI documents the recurrent structural findings (corpus callosum
dysplasia/thinning, lateral-ventricle dilatation, cortical volume loss) and
is proposed to provide neuroimaging clues supporting early diagnosis.
diagnosis_term:
preferred_term: brain magnetic resonance imaging
term:
id: NCIT:C16809
label: Magnetic Resonance Imaging
results: Corpus callosum dysplasia/thinning, dilated lateral ventricles, cortical volume loss.
evidence:
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "we suggest that some neuroimaging clues can be relevant for an early diagnosis"
explanation: Neuroimaging clues are proposed to support early diagnosis of APMR4.
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "highlights the importance of performing brain imaging in LSS-related conditions"
explanation: Brain imaging is recommended in the workup of LSS-related conditions including APMR4.
animal_models:
- name: Lss-null mouse (IMPC Lss tm1b(KOMP)Wtsi homozygote)
species: Mouse
genotype: Lss tm1b(KOMP)Wtsi homozygous (complete loss of function)
publication: PMID:30723320
description: >-
Homozygous Lss-null mice from the International Mouse Phenotyping Consortium
show variable lethality, evidencing that complete loss of lanosterol
synthase activity is not compatible with survival - consistent with the
absence of biallelic complete-null genotypes among human APMR4 patients, who
instead retain hypomorphic (usually missense) alleles.
modeled_mechanisms:
- target: Biallelic LSS Loss-of-Function
relationship: PERTURBS
fidelity: MODERATE
description: >-
Germline null models the complete-loss-of-function extreme of the LSS
allelic series; its lethality delimits why viable human APMR4 requires
residual enzyme activity.
limitations: >-
The homozygous null is variably embryonic-to-perinatal lethal, so it does
not recapitulate the viable, hypomorphic human APMR4 phenotype (alopecia,
intellectual disability); it models the lethality of total LOF rather than
the disease itself.
readouts:
- name: Homozygous-null viability
target: Biallelic LSS Loss-of-Function
direction: DECREASED
interpretation: Complete LSS loss is not survivable, bounding the tolerated end of the allelic series.
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "demonstrate variable lethality, from embryonic day 9.5 to postnatal prior to weaning"
explanation: IMPC Lss-null homozygotes show variable lethality, the readout behind the viability claim.
evidence:
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "demonstrate variable lethality, from embryonic day 9.5 to postnatal prior to weaning"
explanation: Supports treating the Lss-null mouse as informative for the complete-LOF extreme of the trigger node.
discussions:
- discussion_id: apmr4_pathogenesis_gap
kind: KNOWLEDGE_GAP
attaches_to:
- pathophysiology#Impaired Neurodevelopment
prompt: >-
How does partial loss of lanosterol synthase produce alopecia and
neurodevelopmental impairment when circulating cholesterol and its precursors
remain normal?
rationale: >-
Plasma sterol quantification is unremarkable in APMR4, so a simple systemic
cholesterol-deficiency model does not account for the phenotype. Whether the
mechanism is tissue-local cholesterol shortfall in high-demand compartments
(brain, hair follicle), accumulation of an upstream substrate/oxysterol, or a
non-catalytic role of LSS is unresolved, and the pathogenesis has been
explicitly described as poorly understood.
evidence:
- reference: PMID:38800572
reference_title: "Clinical and genetic analyses of APMR4 syndrome caused by novel biallelic LSS variants."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the pathogenesis of APMR4 is poorly understood"
explanation: The molecular pathogenesis linking LSS deficiency to the phenotype is unresolved.
- reference: PMID:30723320
reference_title: "Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Quantification of cholesterol and its precursors did not reveal noticeable imbalance."
explanation: Normal systemic sterols argue against a simple systemic-deficiency mechanism.
- reference: PMID:37157980
reference_title: "Novel LSS variants in alopecia and intellectual disability syndrome: New case report and clinical spectrum of LSS-related rare disease traits."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "normal plasma cholesterol level was reported in several patients with LSS-related disorders supporting an alternative pathway for cholesterol synthesis"
explanation: Normal plasma cholesterol despite the LSS block is proposed to reflect an alternative cholesterol-synthesis route - a central part of the open pathogenesis question.
notes: >
APMR4 is one molecularly characterized member of the alopecia-intellectual
disability syndrome (APMR) group (MONDO:0008756). NEC caution: the parent issue
and dashboard hint attributed APMR1 to LSS and APMR3 to C3orf52; both are
incorrect (a live Named Entity Confusion example). The verified attributions are
APMR1 = AHSG (MONDO:0021035, OMIM 203650) and APMR4 = LSS (this entry,
MONDO:0030009, OMIM 618840); C3orf52 causes a distinct non-syndromic autosomal
recessive hypotrichosis with no intellectual disability and is unrelated to
APMR. APMR2 (MONDO:0012487) and APMR3 (MONDO:0013492) remain locus-only,
uncharacterized. Because APMR types are genetically distinct diseases, the group
should be modeled as a kb/groupings/ Grouping over separate member Disease
entries (per issue #8727) rather than a single umbrella Disease with
has_subtypes; that grouping is deferred until at least a second member (e.g.
AHSG/APMR1) is curated.
Overview. Alopecia-Intellectual Disability Syndrome 4 (APMR4, also written "Alopecia-Mental Retardation Syndrome 4") is an ultra-rare autosomal recessive neuroectodermal disorder caused by biallelic loss-of-function or hypomorphic variants in LSS (lanosterol synthase), the enzyme catalyzing the first committed step of cholesterol biosynthesis. The syndrome is defined by congenital, complete alopecia (alopecia universalis) present from birth, combined with variable intellectual disability/developmental delay, frequently accompanied by early-onset epilepsy, ichthyosiform/scaly skin, and a range of dysmorphic, skeletal, ophthalmologic, and neuroimaging abnormalities. It was originally described under the umbrella term "alopecia-mental retardation syndrome" (APMR), a genetically heterogeneous group now split into at least four numbered loci (APMR1–4), of which APMR4/LSS is the most extensively characterized.
Key identifiers: | Resource | ID | |---|---| | OMIM (phenotype) | #618840 — ALOPECIA-INTELLECTUAL DISABILITY SYNDROME 4; APMR4 | | OMIM (gene/locus) | *600909 — LANOSTEROL SYNTHASE; LSS | | MONDO | MONDO:0030009 | | MedGen | C5394241 | | GTR condition | C5394241 | | Gene | LSS, HGNC gene ID 4047, chromosome 21q22.3 | | Orphanet | Listed under the LSS-associated disease group (Alopecia–mental retardation syndrome / APMR spectrum) |
Synonyms: Alopecia-mental retardation syndrome 4; Alopecia universalis-intellectual disability syndrome; APMR4; AIDS4 (informal, not used in dismech due to acronym collision); older umbrella term "alopecia-mental retardation syndrome" (APMR) prior to genetic dissection into APMR1 (AHSG, 3q27), APMR2 (locus 3q26.2-q26.31, gene unknown), APMR3 (locus 18q11.2-q12.2, gene unknown), and APMR4 (LSS, 21q22.3).
⚠️ Curation/NEC caution: APMR1–4 is a numbered disease series with distinct causal genes and loci sharing only the clinical descriptor "alopecia-mental retardation." APMR1 is caused by AHSG (alpha-2-HS-glycoprotein, chr3q27; OMIM #203650), not LSS. Any literature search on "alopecia mental retardation syndrome" without a number qualifier risks conflating APMR1 (AHSG) with APMR4 (LSS) — this is exactly the Named Entity Confusion pattern flagged in dismech's curation guidance for numbered series. Confirm gene = LSS and OMIM = 618840 (not 203650) before citing.
Data provenance: The information below is aggregated from disease-level curated resources (OMIM, Orphanet, MedGen, GARD, MalaCards) and from individual patient/family case reports and case series in the peer-reviewed literature (not raw EHR data).
Sources: OMIM #618840, OMIM *600909, GTR C5394241, Monarch MONDO:0030009, GARD
Disease causal factor: Biallelic (homozygous or compound heterozygous) pathogenic variants in LSS, which encodes lanosterol synthase — genetic, monogenic, autosomal recessive. There is no known environmental, infectious, or purely mechanistic cause; this is a Mendelian inborn error of sterol biosynthesis.
Genetic risk factors: - Being a compound heterozygote or homozygote for pathogenic LSS variants (missense, nonsense, frameshift, and splice-site variants have all been reported). - Consanguinity is a recurrent risk factor — the founding families (Swiss-origin, Turkish, Pakistani, Iranian, Egyptian, Chinese) were frequently consanguineous or from populations with elevated consanguinity rates, consistent with autosomal recessive inheritance and regional founder alleles. - No specific population founder variant has risen to prominence the way some AR disorders have; the reported variant spectrum is largely private/family-specific across ~30 families cumulatively reported as of 2024–2025.
Environmental/lifestyle risk factors: None established; this is a purely monogenic disorder with no reported environmental modifiers of onset.
Protective factors: None specifically documented in the literature (no protective alleles or environmental protective factors reported for APMR4 itself). By analogy to other cholesterol pathway disorders, residual enzymatic activity from hypomorphic (vs. null) alleles appears to correlate with milder phenotype (genotype-phenotype correlation noted by Elbendary et al. 2023, PMID:37157980), functioning as a partial "protective" gradient rather than a discrete factor.
Gene-environment interactions: Not established for APMR4. The disease is driven by loss of enzymatic function; no interaction with diet, toxins, or other environmental exposures has been reported to modify phenotype expression.
Suggested ontology terms: HP:0000006 (Autosomal recessive inheritance); hgnc:LSS (verify HGNC numeric ID via OAK); MONDO:0030009.
Phenotype data below is synthesized from OMIM's clinical synopsis (#618840), the original Besnard/Romani et al. 2019 cohort (10 patients, 6 families; PMID:30723320), and subsequent case reports/series (Elbendary 2023, PMID:37157980; a 2022 case report PMC9726667; a 2024 Frontiers case series PMC11116803/PMID:38800572; and additional Chinese case reports).
HP:0008064 (Ichthyosis) / HP:0007503 (Generalized ichthyosis) — verify.HP:0001249 (Intellectual disability).HP:0001250 (Seizure), HP:0011097 (Epileptic spasm, if applicable), HP:0002194 (Delayed gross motor development).HP:0000252 (Microcephaly).HP:0002079 (Hypoplasia of the corpus callosum), HP:0002119 (Ventriculomegaly).HP:0000028 (Cryptorchidism), HP:0000054 (Micropenis).HP:0000518 (Cataract), HP:0000640 (Nystagmus).Causal gene: LSS (Lanosterol Synthase; HGNC symbol LSS; OMIM *600909), located at 21q22.3. The gene is also known by alternate names APMR4, CTRCT44, HYPT14, OSC (2,3-oxidosqualene-lanosterol cyclase).
Gene function: LSS encodes 2,3-oxidosqualene–lanosterol cyclase, an ER-membrane-anchored enzyme that catalyzes the cyclization of (S)-2,3-oxidosqualene into lanosterol — the first committed and rate-limiting cyclization step of cholesterol, steroid hormone, and vitamin D biosynthesis downstream of the mevalonate pathway. LSS localizes to the endoplasmic reticulum membrane (cytoplasmic face) and has also been detected on lipid droplets. - GO Molecular Function: GO:0000250 (lanosterol synthase activity) - GO Biological Process: GO:0006695 (cholesterol biosynthetic process) - GO Cellular Component: endoplasmic reticulum membrane (verify precise GO CC ID via OAK, e.g., GO:0005789)
Variant classification/type: Reported pathogenic LSS variants causing APMR4 span the full spectrum — missense (the majority, ~9 of a compiled set), nonsense (~2), splice-site (~2, including a documented exon-12-skipping intronic variant, NM_002340.6:c.1194+5G>A, ClinVar RCV001034702, pathogenic), and frameshift (~1) variants, plus at least one large gross deletion involving LSS (reported in a Chinese patient). Compound heterozygosity (missense + nonsense, or missense + splice) is common given the rarity of the disease and low consanguinity in some reported families.
Representative variants: - c.401T>G (p.Val134Gly, missense) / c.369C>G (p.Tyr123*, nonsense) — compound heterozygous, Chinese patient (Frontiers 2024 case series; PMC11116803/PMID:38800572). The nonsense allele reduced LSS protein by ~50% on western blot; the missense allele was predicted destabilizing by multiple in-silico tools (DynaMut, mCSM, SDM, DUET). - c.14+2T>C (splice) / c.1357G>A (p.Val453Leu, missense) — compound heterozygous, Egyptian patient with cerebellar involvement (Elbendary et al. 2023, PMID:37157980). - c.1194+5G>A (splice, exon 12 skipping) — compound heterozygous, Turkish siblings (Besnard/Romani et al. 2019, PMID:30723320; ClinVar RCV001034702).
Allele frequency: Novel variants reported to date are generally absent or extremely rare in population databases (gnomAD/1000 Genomes), consistent with a very rare recessive disease; no specific population allele frequencies for LSS pathogenic alleles were identified in the sources reviewed. gnomAD-derived constraint metrics (pLI/LOEUF) specific to LSS were not directly retrieved in this search and should be verified directly in the gnomAD browser before citation.
Somatic vs. germline: All reported APMR4 variants are germline, biallelic, autosomal recessive.
Functional consequence: Predominantly loss of function / partial loss of function (hypomorphic) — nonsense/frameshift/canonical splice variants cause truncation or reduced protein; missense variants are predicted/shown to destabilize the folded enzyme (in silico stability predictions; some with demonstrated reduced protein by western blot). No gain-of-function or dominant-negative mechanism has been reported for APMR4-associated LSS alleles.
Modifier genes: None specifically established for APMR4. Emerging genotype-phenotype correlation observations (Elbendary et al. 2023, reviewing variants across 30 families) suggest variant type/residual activity — rather than a distinct modifier locus — accounts for much of the phenotypic heterogeneity between the hypotrichosis-only, cataract-only, and full APMR4 syndromic presentations.
Epigenetic information: No disease-specific epigenetic (DNA methylation/histone) studies for LSS/APMR4 were identified in this search.
Chromosomal abnormalities: APMR4 is caused by point mutations/small indels/splice variants in the vast majority of cases; however, at least one gross (large) deletion involving LSS has been reported in a Chinese patient (Liu et al., Journal of Dermatology, in combination with a known missense allele on the other chromosome), indicating that copy-number/deletion/duplication analysis is a clinically offered test modality (per GTR).
Allelic disorders (same gene, distinct phenotypes) — important for scope/differential diagnosis: | Disorder | OMIM | Phenotype | |---|---|---| | Alopecia-Intellectual Disability Syndrome 4 (APMR4) | #618840 | Alopecia universalis + intellectual disability ± epilepsy (this entry) | | Hypotrichosis 14 (HYPT14) | — | Isolated/nonsyndromic sparse hair, no intellectual disability | | Cataract 44 (CTRCT44) | — | Isolated early-onset/congenital cataract | | Congenital Alopecia-Cataract Syndrome (CACS) | (recently proposed, e.g. PMID:39436000) | Alopecia + cataract + esotropia/nystagmus, without prominent ID | | Autosomal recessive palmoplantar keratoderma with congenital alopecia, type 2 | — | Palmoplantar keratoderma + alopecia |
This allelic spectrum indicates LSS-related disease is best conceptualized as a phenotypic continuum governed largely by residual enzyme activity and tissue-specific vulnerability (skin/hair follicle, lens, and — for the more severe end — CNS), rather than discrete non-overlapping diseases.
Sources: OMIM *600909, Besnard et al. 2019 Genet Med, PMID:30723320, Elbendary et al. 2023 Clin Genet, PMID:37157980, Frontiers 2024 case series, PMID:38800572, ClinVar RCV001034702
No environmental, lifestyle, or infectious contributing factors have been identified or proposed in the literature for APMR4 — it is a purely monogenic disorder. No relevant CTD, TOXNET, or infectious-agent associations were found.
Causal chain (proposed, from genetic lesion to clinical phenotype):
Cell types and biological processes involved: - Epidermal keratinocytes and hair follicle epithelium (barrier formation, folliculogenesis) — suggested CL term: keratinocyte (CL:0000312), hair follicle stem cell. - Lens epithelial/fiber cells — suggested CL term: lens fiber cell (CL:0011004). - Neurons/glia (CNS, less directly modeled) — suggested CL term: neuron (CL:0000540).
Protein dysfunction: Missense variants are predicted (and in one case demonstrated by reduced protein on western blot) to cause protein misfolding/destabilization rather than catalytic-site disruption alone; nonsense/frameshift/canonical-splice variants cause truncation and loss of protein, consistent with an overall loss-of-function mechanism.
Metabolic changes: Localized disruption of the sterol/lipid biosynthetic pathway at the lanosterol cyclization step; downstream cholesterol, steroid hormone, and vitamin D synthesis are potentially affected in a tissue-restricted manner, but systemic serum cholesterol is generally preserved — an important distinguishing biochemical feature from other cholesterol-synthesis disorders.
Immune system involvement: Not a primary feature; no autoimmune or immunodeficiency component has been established (in contrast to alopecia areata/universalis of autoimmune etiology, which is a different, non-genetic condition and should not be conflated with APMR4's congenital genetic alopecia).
Tissue damage mechanisms: Barrier dysfunction and desmosomal hypoplasia in skin (documented in the mouse model); no oxidative-stress, fibrotic, or ischemic mechanism has been specifically implicated.
Molecular/omics profiling: No transcriptomic, proteomic, or single-cell datasets specific to human LSS/APMR4 disease tissue were identified in this search; the closest available functional data are the murine tissue-specific knockout studies (Wada et al. 2020) and targeted protein-stability/expression assays performed on patient-derived variants (western blot, qPCR, in silico stability prediction) in recent case reports.
Sources: Wada et al. 2020 PLOS Genetics, "Metabolic and pathologic profiles of human LSS deficiency recapitulated in mice", Frontiers 2024 case series
Organ level: - Primary: Skin/integument (scalp, body — alopecia, ichthyosis), and (via allelic overlap) the eye (lens — cataracts). - Secondary: Central nervous system (intellectual disability, epilepsy, corpus callosum hypoplasia, cerebellar involvement in some), skeletal system (short stature, joint hyperextensibility), genitourinary system (cryptorchidism, micropenis), craniofacial skeleton (dysmorphism), teeth (mineralization defects). - Body systems involved: Integumentary, nervous, skeletal, ophthalmologic, genitourinary.
Tissue/cell level: - Epidermis and hair follicle (keratinocytes, follicular epithelium, desmosomes). - Lens epithelium/fiber cells. - CNS neurons/white matter (corpus callosum), cerebellum (vermis) in a subset.
Subcellular level: - Endoplasmic reticulum membrane — site of LSS enzymatic activity (GO cellular component, ER membrane). - Lipid droplets — secondary LSS localization site.
Localization: Scalp, eyebrows, eyelashes, and total body hair (alopecia universalis — generalized, not lateralized); skin generally (ichthyosis/erythroderma); lens (bilateral cataracts when present); corpus callosum (midline structure, symmetric hypoplasia); cerebellar vermis (midline, in the subset with ataxia).
Suggested UBERON terms: UBERON:0002073 (hair follicle) / UBERON:0000014 (zone of skin), UBERON:0000965 (lens of camera-type eye), UBERON:0002336 (corpus callosum), UBERON:0002037 (cerebellum) — verify via OAK.
Epidemiology: - Prevalence: Predicted at less than 1 in 1,000,000 worldwide (OMIM/GTR estimate); the broader APMR spectrum (all loci combined) has been estimated at ~1 in 1,000,000. - Cumulative reported cases: approximately 30 families with LSS-related phenotypes (spanning APMR4, hypotrichosis 14, cataract 44, and CACS) as reviewed by Elbendary et al. 2023; the APMR4/syndromic-ID subset specifically comprises on the order of ~16+ individuals across the case reports reviewed here (10 in the original 2019 description, plus additional cases in 2022–2024 reports), an underestimate given ongoing publication of new families.
Inheritance pattern: Autosomal recessive.
Penetrance: Appears to be high/complete for alopecia (essentially 100% of biallelic-variant carriers manifest alopecia universalis at birth in the reported literature) but variable for intellectual disability severity and epilepsy, consistent with an emerging genotype-phenotype correlation tied to variant type/residual enzyme activity rather than incomplete penetrance per se.
Expressivity: Highly variable — intellectual disability ranges from mild to severe; not all patients have epilepsy, cataracts, or cerebellar findings; this variable expressivity across the LSS allelic series (isolated hypotrichosis vs. isolated cataract vs. full APMR4 syndrome vs. CACS) is a defining feature of this gene's disease spectrum.
Genetic anticipation: Not reported/applicable (not a repeat-expansion disorder).
Germline mosaicism: Not specifically documented for LSS/APMR4 in the sources reviewed.
Founder effects: No single dominant founder allele has been identified across the multiple ethnically diverse families reported (Swiss, Turkish, Pakistani, Iranian, Egyptian, Chinese); variants appear largely private/family-specific, though consanguinity is a recurrent contributing factor in several reported kindreds.
Consanguinity role: Prominent in several of the founding and subsequently reported families, consistent with autosomal recessive inheritance of rare alleles.
Carrier frequency: Not established/reported in population databases for LSS pathogenic alleles specifically.
Population demographics: - Affected populations: Cases reported from diverse ancestries — Swiss, Turkish, Pakistani, Iranian, Egyptian (Middle Eastern/North African), and Chinese (East Asian) families — indicating the disorder is panethnic rather than confined to a specific founder population, though most series note consanguineous unions. - Geographic distribution: Global/sporadic case reports; no endemic focus described. The 2024 Frontiers case series is explicitly noted as "the first study in Asia to date," reflecting expanding geographic recognition. - Sex ratio: No skewed sex ratio reported (autosomal recessive; both sexes affected); genitourinary features (cryptorchidism, micropenis) are naturally male-specific findings. - Age distribution: All reported patients are pediatric at time of description (congenital onset with recognition in infancy/early childhood); long-term adult natural history data are limited given the rarity and recency of gene discovery (2019).
Clinical recognition: Congenital alopecia universalis + developmental delay/intellectual disability ± seizures ± characteristic dysmorphism (frontal bossing, large ears) ± scaly skin is the clinical trigger for suspicion.
Laboratory tests: - Routine serum lipid panel (cholesterol) — typically normal, which is itself diagnostically informative (distinguishes from Smith-Lemli-Opitz syndrome and other cholesterol-synthesis disorders with low serum cholesterol/elevated 7-dehydrocholesterol). - Specialized/research-level sterol profiling of skin sebum (epoxysqualene:lanosterol ratio) has been used as a biochemical confirmatory biomarker in research settings (Wada et al. 2020) but is not a standard clinical test.
Genetic testing: - Single-gene LSS sequencing or targeted alopecia/ID gene panels are the primary diagnostic approach once the phenotype is recognized. - Whole exome sequencing (WES) has been the diagnostic method in most reported families, given the rarity and non-specific overlap of the phenotype with other syndromic intellectual disability/ectodermal dysplasia disorders. - Chromosomal microarray / deletion-duplication analysis is relevant given the reported gross LSS deletion in at least one patient; GTR lists deletion/duplication analysis as an available clinical test modality for this condition. - Variant classification follows standard ACMG/AMP guidelines; reported variants have been classified pathogenic/likely pathogenic based on rarity in population databases, in silico predictions, and (in some studies) functional protein studies.
Imaging: - Brain MRI is recommended in the diagnostic workup given the high yield of abnormalities (7/9 imaged patients in the OMIM-reviewed cohort had nonspecific abnormalities, most often corpus callosum hypoplasia). - Ophthalmologic exam (slit-lamp) to assess for cataract given the allelic overlap with CTRCT44/CACS.
Electrophysiology: EEG/video-EEG indicated in patients with seizures; reported findings include spike-wave discharges maximal over occipital/posterior temporal regions.
Biopsy/histopathology: Skin biopsy is not a standard diagnostic requirement but research histology (in the mouse model) shows hyperkeratosis, psoriasiform acanthosis, hypoplastic hair follicles, and thin outer root sheaths — findings that could in principle be seen on human skin biopsy though this is not established as a routine clinical diagnostic step.
Differential diagnosis: Other syndromic congenital alopecias/hypotrichoses with intellectual disability (e.g., APMR1/AHSG, APMR2, APMR3 — distinct loci); Netherton syndrome; trichothiodystrophy; other ectodermal dysplasias with CNS involvement; Smith-Lemli-Opitz syndrome and other cholesterol biosynthesis disorders (distinguished by normal serum cholesterol in APMR4 vs. abnormal in SLOS); alopecia areata/universalis (autoimmune, acquired, not congenital, and without intellectual disability — an important distinguishing feature since the name "alopecia universalis" is shared but the etiology is entirely different).
Screening: No population-based newborn or carrier screening program exists for this ultra-rare disorder; diagnosis is case-by-case following clinical suspicion.
Survival/mortality: No mortality data specific to APMR4 was identified in the sources reviewed; the disorder does not appear to be associated with reduced life expectancy per se (in contrast to the mouse epidermis-specific full knockout, which is neonatally lethal from dehydration/barrier failure — a more severe model than the human hypomorphic disease). No formal survival statistics (5-year/10-year) exist given the rarity and recency of characterization.
Morbidity: Chronic disability from intellectual disability (ranging mild to severe) and, in the subset with epilepsy, seizure-related morbidity. Alopecia itself, while not medically dangerous, carries psychosocial morbidity.
Complications: Uncontrolled epilepsy (requiring combination antiepileptic therapy in reported cases); potential visual impairment in patients with the overlapping cataract phenotype; barrier-related skin complications (ichthyosis/erythroderma) may predispose to secondary skin issues, by analogy with other ichthyosiform disorders, though this was not explicitly reported.
Recovery potential: Alopecia does not spontaneously resolve in humans (unlike the reversible pattern seen after acute inducible gene deletion in the mouse model); intellectual disability is a static, non-recoverable developmental phenotype, though early intervention (physical/occupational/speech therapy) can improve functional outcomes as in other neurodevelopmental disorders generally.
Prognostic factors: Emerging genotype-phenotype correlation — variant type and predicted residual enzymatic activity correlate with severity across the LSS allelic spectrum (isolated hypotrichosis at the mild end, full APMR4 syndrome with severe ID/epilepsy at the more severe end), per Elbendary et al. 2023's review of 30 families.
No disease-specific or FDA-approved treatment exists for APMR4; management is entirely supportive and symptomatic, coordinated by a multidisciplinary team (genetics, neurology, dermatology, ophthalmology as needed) per GARD guidance.
Pharmacotherapy (symptomatic, for seizures): In one reported case, seizure control was achieved via sequential/combination antiepileptic therapy:
- Topiramate monotherapy (up to 6 mg/kg/day) — insufficient alone.
- Valproic acid (30 mg/kg/day) added in combination with topiramate — reduced seizure frequency.
- Clonazepam (0.2 mg/kg/day maintenance) added — achieved seizure control, with sustained remission reported even after topiramate withdrawal.
- Suggested NCIT term: NCIT:C15632 (or more specifically an antiepileptic pharmacotherapy term) for anticonvulsant treatment; NCIT:C15986 (Pharmacotherapy) as the general treatment term with therapeutic_agent bound to CHEBI terms for topiramate, valproic acid, and clonazepam.
Dermatologic management: No curative treatment for the alopecia; management is cosmetic/supportive (wigs, emollients for scaly skin) — analogous to management of other congenital alopecias, though not specifically detailed in the retrieved literature for APMR4.
- Suggested NCIT term: NCIT:C15747 (Supportive Care).
Ophthalmologic management (for overlapping cataract phenotype): Cataract extraction surgery, as standard for congenital/pediatric cataracts, would be the expected intervention in patients with significant lens opacity, by analogy to management of CTRCT44/CACS, though this was not explicitly detailed as performed in an APMR4-specific case in the sources reviewed.
- Suggested NCIT term: NCIT:C15329 (Surgical Procedure).
Developmental/rehabilitative support: Physical therapy, occupational therapy, and speech therapy are standard supportive interventions for intellectual disability/developmental delay, per general GARD guidance for this condition category.
- Suggested NCIT terms: NCIT:C15302 (Physical Therapy), NCIT:C159273 (Speech Therapy), NCIT:C121351 (Occupational Therapy).
Genetic counseling: Recommended for affected families given the 25% recurrence risk in future pregnancies for carrier parents (autosomal recessive).
- Suggested NCIT term: NCIT:C15240 (Genetic Counseling).
Experimental/investigational therapies: No gene therapy, RNA-based therapy, or targeted molecular therapy trials specific to LSS/APMR4 were identified in ClinicalTrials.gov searches performed as part of this research (GARD explicitly notes no FDA-approved treatments and directs families toward general rare-disease clinical trial resources). Given the tissue-restricted (rather than systemic) biochemical defect, statin-based or other systemic cholesterol-modulating therapy would not be expected to be beneficial and has not been proposed in the literature reviewed.
Treatment outcomes/response rates: No systematic treatment-response data exist beyond the single reported seizure-management case detailed above; this reflects the extreme rarity and recency of syndrome characterization rather than an absence of effective options being tested.
Primary prevention: Not applicable in the traditional sense (monogenic recessive disorder); the only "primary prevention" avenue is reproductive/genetic counseling for known carrier couples, including discussion of prenatal diagnosis or preimplantation genetic diagnosis (PGD) for families with a previously affected child and a known biallelic LSS genotype, though no specific literature on PGD use for this condition was identified.
Secondary prevention: Early genetic diagnosis in an affected infant (recognizing congenital alopecia + developmental concern early) can enable earlier initiation of developmental/early-intervention services and closer seizure surveillance, potentially improving functional outcomes, though no formal outcomes study of early- vs. late-diagnosed cohorts exists.
Screening: No population or newborn screening program exists; carrier screening would only be relevant in the context of a known family history (cascade testing of at-risk relatives) given the ultra-rare, non-founder-population nature of the disease.
Genetic counseling: Central to prevention discussion — informing carrier parents of the 25% recurrence risk per pregnancy and discussing reproductive options.
Public health/behavioral/immunization/prophylaxis: Not applicable — no infectious, environmental, or behavioral prevention avenues exist for this monogenic disorder.
Naturally occurring disease in other species: No naturally occurring veterinary/companion-animal case of LSS-related alopecia-intellectual disability syndrome was identified in this search (no OMIA entry located for this specific phenotype-gene pairing). This does not rule out veterinary relevance but no supporting citation was found.
Orthologous gene: Mouse Lss (Lanosterol synthase; MGI ortholog of human LSS) — the principal model organism used to study LSS loss of function (see Model Organisms below). Rat Lss ortholog is also curated in RGD.
Comparative biology: The core enzymatic function (oxidosqualene cyclization to lanosterol) is deeply conserved across vertebrates as part of the essential mevalonate/cholesterol biosynthetic pathway, consistent with the embryonic/perinatal lethality of complete Lss loss in mouse models (see below) — indicating the human disease-causing alleles are necessarily hypomorphic/tissue-restricted rather than complete nulls, since a true systemic null is likely incompatible with life.
Zoonotic potential / cross-species transmission: Not applicable (non-infectious, monogenic disorder).
The best-characterized model system for LSS deficiency is the mouse (Mus musculus), described in Wada et al. 2020, PLOS Genetics 16(2):e1008628, "Metabolic and pathologic profiles of human LSS deficiency recapitulated in mice."
Model types and key findings:
Fidelity/relevance: HIGH fidelity for the epidermal barrier and follicular component of the human phenotype, though the neonatal lethality is more severe than the human (hypomorphic-allele) disease, consistent with these being complete nulls vs. the partial-function human alleles.
Tamoxifen-inducible epidermal knockout (Lss^f/f;K14-CreERT) — allows postnatal, temporally controlled Lss deletion in skin, avoiding developmental lethality.
Relevance: This inducible model most directly recapitulates the human dermatologic phenotype (alopecia, scaly/hyperkeratotic skin) in a way that is survivable and can be studied longitudinally.
Lens-specific knockout (Lss^f/f;Pax6-Cre) — targets Lss deletion to the lens.
Biochemical validation in the model: The mouse studies established the (S)-2,3-epoxysqualene:lanosterol ratio elevation in sebum as a translatable biomarker, subsequently confirmed in human patient sebum samples — with blood/plasma cholesterol remaining normal in both species, supporting a tissue-autonomous rather than systemic disease mechanism.
Model limitations: The full constitutive epidermal knockout is neonatally lethal and thus more severe than typical human hypomorphic disease, limiting its use for long-term phenotypic/therapeutic study; the models are tissue-restricted (epidermis or lens specifically) rather than whole-organism hypomorphic knock-ins carrying actual patient-equivalent missense alleles, so they do not directly model the neurodevelopmental (CNS) component of human APMR4 (intellectual disability, epilepsy, corpus callosum hypoplasia) — this remains an important gap in the animal-model literature and a candidate HUMAN_MODEL_MISMATCH/knowledge-gap area for curation (no CNS-specific Lss conditional knockout phenotype was identified in this search).
Research applications: These models are useful for studying epidermal/follicular barrier biology, lens sterol metabolism, and for validating tissue-specific sterol biomarkers, but a hypomorphic whole-organism or CNS-conditional model recapitulating the neurodevelopmental phenotype has not yet been reported in the literature retrieved.
Resources: MGI (Mouse Genome Informatics) — Lss mouse gene page; RGD (Rat Genome Database) — Lss rat gene page (rgd.mcw.edu, gene ID 620955).
Sources: Wada et al. 2020 PLOS Genetics, RGD Lss gene page
| Claim | PMID / Source |
|---|---|
| Original genetic description: 10 patients, 6 families, biallelic LSS variants causing recessive neuroectodermal APMR syndrome | Besnard/Romani et al. 2019, Genet Med 21:2025-2035, PMID:30723320 |
| OMIM disease/gene entries | OMIM #618840 (phenotype), OMIM *600909 (gene) |
| Novel splice-site + missense variant, Egyptian patient, cerebellar involvement, review of 30 families | Elbendary et al. 2023, Clin Genet, PMID:37157980 |
| Chinese patient, compound het missense/nonsense, functional protein studies, first Asian case series, literature comparison table | Frontiers in Neuroscience 2024, PMID:38800572 (PMC11116803) |
| Case report expanding phenotypic spectrum, novel variant | PMC9726667 (2022) |
| Mouse tissue-specific Lss knockouts recapitulating skin barrier, alopecia, and cataract phenotypes; sebum biomarker | Wada et al. 2020, PLOS Genetics 16(2):e1008628 |
| AHSG/APMR1 background (differential/NEC caution) | Reza Sailani et al. 2017; Muzammal et al. 2021, Ann Hum Genet, PMID:33881165 |
| Gross LSS deletion, Chinese patient | Liu et al., J Dermatol (Wiley) |
| Congenital alopecia-cataract syndrome (allelic phenotype) | PMID:39436000 |
Data gaps flagged for curation: No CNS/neuron-specific animal model exists to directly test the mechanism of intellectual disability/epilepsy; no formal QoL instrument data; no gnomAD constraint metrics for LSS were independently verified in this search (recommend direct gnomAD browser lookup before curation); exact HPO term IDs suggested above should be verified with runoak/OAK per the standard ontology-term verification workflow before being committed to a knowledge base entry.
Sources: - OMIM #618840 - OMIM *600909 - GTR C5394241 - MalaCards APMR4 - Monarch MONDO:0030009 - GARD Alopecia-intellectual disability syndrome - Besnard et al. 2019, PMID:30723320 - Elbendary et al. 2023, PMID:37157980 - Frontiers in Neuroscience 2024 case series, PMID:38800572 - Expanding Phenotypic Spectrum case report, PMC9726667 - Wada et al. 2020, PLOS Genetics mouse model - ClinVar RCV001034702 - Muzammal et al. 2021 APMR review, PMID:33881165 - AHSG/APMR1 association paper - Congenital alopecia-cataract syndrome, PMID:39436000
Checked with linkml-reference-validator 0.2.1.
| Outcome | Count |
|---|---|
| References checked | 10 |
| Resolved | 10 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
All extracted references resolved successfully.